Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.
TALAPRO-2 Data Support Approval of Talazoparib/Enzalutamide in HRR-Mutant mCRPC
June 21st 2023Karim Fizazi, MD, discusses findings from the phase 3 TALAPRO-2 trial which support the recent FDA approval of talazoparib plus enzalutamide in homologous recombination repair gene-mutated metastatic castration resistant prostate cancer.
Watch
KEYNOTE-826 Data Confirm Survival Benefit of Pembrolizumab Addition in Cervical Cancer
June 16th 2023In an interview with Targeted Oncology, Bradley J. Monk, MD, FACCOG, FACS, highlighted final results from the phase 3 KEYNOTE-826 trial of pembrolizumab plus chemotherapy vs chemotherapy plus placebo, with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer.
Read More
Dramatic Changes in the RCC Landscape Underscore Importance of Molecular Profiling
June 8th 2023In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.
Read More
Guidance on Treating GIST in the Second-Line and Beyond
May 30th 2023In an interview with Targeted Oncology, Alexander Helfand, MD, discussed the treatment of GIST in the second-line setting, as well as later lines, including the available options, guideline recommendations, and ongoing research.
Read More
SunRISE Program Incites Optimism About the Future of High-Risk, BCG-Unresponsive NMIBC Treatment
May 24th 2023In an interview with Targeted Oncology, Siamak Daneshmand, MD, discussed TAR-200 as seen in the SunRISE-1 trial and the what is up next for the treatment landscape of high-risk BCG-unresponsive non-muscle invasive bladder cancer.
Read More